TY - JOUR
T1 - The Influence of Migraine on Driving
T2 - Current Understanding, Future Directions, and Potential Implications of Findings
AU - Tepper, Stewart J.
AU - Silberstein, Stephen D.
AU - Rosen, Noah L.
AU - Lipton, Richard B.
AU - Dennehy, Ellen B.
AU - Dowsett, Sherie A.
AU - Doty, Erin
N1 - Funding Information:
The impact of migraine on driving performance has been largely neglected, with few studies specifically designed to address the topic, and relevant studies were generally small with limited control of confounders. This area requires more focus, given a potential for impact on road safety. Financial Support: This review paper was a collaboration between Eli Lilly and Company and migraine experts external to Lilly. Three authors on this paper are full time employees at Eli Lilly and Company. Authors external to Lilly were not reimbursed for their involvement in writing this paper. All other conflicts are disclosed in the conflicts of interest statement. Conflict of Interest: ST – Grants for research (no personal compensation): Alder, Allergan, Amgen, Dr. Reddy's, ElectroCore, Eli Lilly, eNeura, Neurolief, Novartis, Scion Neurostim, Teva, Zosano; Consultant and/or Advisory Boards: Acorda, Alder, Alexsa, Allergan, Alphasights, Amgen, Aperture Venture Partners, Aralez Pharmaceuticals Canada, Axsome Therapeutics, BioDelivery Sciences International, Biohaven, Charleston Labs, Decision Resources, DeepBench, Dr. Reddy's, ElectroCore, Eli Lilly, eNeura, Equinox, ExpertConnect, GLG, GSK, Guidepoint Global, Impel, M3 Global Research, Magellan Rx Management, Marcia Berenson Connected Research and Consulting, Medicxi, Navigant Consulting, Neurolief, Nordic BioTech, Novartis, Pfizer, Reckner Healthcare, Relevale, Satsuma, Scion Neurostim, Slingshot Insights, Sorrento, Spherix Global Insights, Sudler and Hennessey, Teva, Theranica, Thought Leader Select, Trinity Partners, XOC, Zosano. Royalties: Springer. Salary: Dartmouth‐Hitchcock Medical Center, American Headache Society. SDS – As a consultant and/or advisory panel member, Dr. Stephen Silberstein receives, or has received, honoraria from Abide Therapeutics; Alder Biopharmaceuticals; Allergan, Inc.; Amgen; Avanir Pharmaceuticals, Inc.; Biohaven Pharmaceuticals; Cefaly; Curelator, Inc.; Dr. Reddy's Laboratories; Egalet Corporation; GlaxoSmithKline Consumer Health Holdings, LLC.; eNeura Inc.; electroCore Medical, LLC; Impel NeuroPharma, Inc.; Eli Lilly USA, LLC; Medscape, LLC; Novartis, Inc.; Satsuma Pharmaceuticals; Supernus Pharmaceuticals, Inc.; Teva Pharmaceuticals; Theranica; and Trigemina, Inc. NLR – Allergan: honoraria for speaking, advisory board and research support. Alder: honoraria for advisory board. Amgen/ Novartis: honoraria for advisory board. Biohaven: honoraria for advisory board. Eli Lilly and Company: honoraria for advisory board, research support. Promius: honoraria for advisory board. Supernus: honoraria for advisory board. Teva: honoraria for advisory board. RBL – Edwin S. Lowe Professor of Neurology at the Albert Einstein College of Medicine in New York. Receives research support from the NIH: 2PO1 AG003949 (mPI), 5U10 NS077308 (PI), R21 AG056920 (Investigator), 1RF1 AG057531 (Site PI), RF1 AG054548 (Investigator), 1RO1 AG048642 (Investigator), R56 AG057548 (Investigator), U01062370 (Investigator), RO1 AG060933 (Investigator), K23 NS09610 (Mentor), K23AG049466 (Mentor), K23 NS107643 (Mentor). Receives support from the Migraine Research Foundation and the National Headache Foundation. Serves on the editorial board of Neurology, senior advisor to Headache, and associate editor to Cephalalgia. Reviewed for the NIA and NINDS, holds stock options in eNeura Therapeutics and Biohaven Holdings; serves as consultant, advisory board member, or has received honoraria from: American Academy of Neurology, Alder, Allergan, American Headache Society, Amgen, Autonomic Technologies, Avanir, Biohaven, Biovision, Boston Scientific, Dr. Reddy's, Electrocore, Eli Lilly and Company, eNeura Therapeutics, GlaxoSmithKline, Merck, Pernix, Pfizer, Supernus, Teva, Trigemina, Vector, Vedanta. Receives royalties from Wolff's Headache 7th and 8th Edition, Oxford Press University, 2009, Wiley and Informa. ED, EBD and SAD are full time employees and minor stock holders at Eli Lilly and Company, IN, USA
Publisher Copyright:
© 2019 Eli Lilly and Company. Headache: The Journal of Head and Face Pain published by Wiley Periodicals, Inc. on behalf of American Headache Society
PY - 2020/1/1
Y1 - 2020/1/1
N2 - Objective: To review the published findings relevant to migraine and driving performance, with an intent to encourage discussion on research which may broaden understanding in this area and help educate healthcare providers and their patients. Background: Motor vehicle crashes result in more than 35,000 deaths and more than 2 million injuries annually in the United States. Migraine is one of the most prevalent diseases in the world, and many symptoms associated with migraine attacks have the potential to negatively influence driving ability. Methods: We reviewed the published findings related to migraine and driving performance. Study findings relevant to symptoms of migraine and their potential effect on driving were also reviewed. This required a more expansive exploration of the literature beyond migraine, for example, review of the literature relating to the effect of pain, sleepiness, visual disturbances, or vertigo on driving. Finally, the potential effects of treatment for migraine on driving were reviewed. Results: Literature on the effect of migraine on driving performance is sparse and, in general published studies on the topic have a number of limitations. Based on review of the literature pertaining to other disorders, it seems feasible that some symptoms occurring as part of the migraine attack could impact driving performance, although formal study in this area is lacking. Many of the approved treatments for migraine have the potential to impact driving, yet this has not been specifically studied, and the extent to which these risks are communicated to patients is not clear. Conclusion: The impact of migraine on driving performance has been largely neglected, with few studies specifically designed to address the topic, and relevant studies were generally small with limited control of confounders. This area requires more focus, given a potential for impact on road safety.
AB - Objective: To review the published findings relevant to migraine and driving performance, with an intent to encourage discussion on research which may broaden understanding in this area and help educate healthcare providers and their patients. Background: Motor vehicle crashes result in more than 35,000 deaths and more than 2 million injuries annually in the United States. Migraine is one of the most prevalent diseases in the world, and many symptoms associated with migraine attacks have the potential to negatively influence driving ability. Methods: We reviewed the published findings related to migraine and driving performance. Study findings relevant to symptoms of migraine and their potential effect on driving were also reviewed. This required a more expansive exploration of the literature beyond migraine, for example, review of the literature relating to the effect of pain, sleepiness, visual disturbances, or vertigo on driving. Finally, the potential effects of treatment for migraine on driving were reviewed. Results: Literature on the effect of migraine on driving performance is sparse and, in general published studies on the topic have a number of limitations. Based on review of the literature pertaining to other disorders, it seems feasible that some symptoms occurring as part of the migraine attack could impact driving performance, although formal study in this area is lacking. Many of the approved treatments for migraine have the potential to impact driving, yet this has not been specifically studied, and the extent to which these risks are communicated to patients is not clear. Conclusion: The impact of migraine on driving performance has been largely neglected, with few studies specifically designed to address the topic, and relevant studies were generally small with limited control of confounders. This area requires more focus, given a potential for impact on road safety.
KW - driving performance
KW - migraine
KW - motor vehicle accident
KW - treatment
UR - http://www.scopus.com/inward/record.url?scp=85076287846&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85076287846&partnerID=8YFLogxK
U2 - 10.1111/head.13716
DO - 10.1111/head.13716
M3 - Article
C2 - 31792964
AN - SCOPUS:85076287846
SN - 0017-8748
VL - 60
SP - 178
EP - 189
JO - Headache
JF - Headache
IS - 1
ER -